A distinct approach to Bcl6 degradation was demonstrated by Słabicki et al. [95], who designed a novel Bcl6-targeting molecule BI-3802 based on in silico studies, which induced rapid Bcl6 degradation at IC50 of less than 3 nM in the SU-DHL4 DLBCL cell line by binding the BTB domain. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.